Idiopathic Pulmonary Fibrosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Idiopathic Pulmonary Fibrosis stocks.

Idiopathic Pulmonary Fibrosis Stocks Recent News

Date Stock Title
May 24 BIIB Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?
May 24 BIIB Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
May 24 VCYT Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
May 24 BIIB The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
May 23 FGEN FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncol...
May 23 BIIB Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
May 23 BIIB Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
May 23 VCYT Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
May 23 BIIB Biogen enters deal to acquire HI-Bio for $1.8bn
May 23 VCYT Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
May 22 VCYT Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
May 22 BIIB Sector Update: Health Care Stocks Slightly Higher Late Afternoon
May 22 BIIB Biogen Agrees to Buy Human Immunology Biosciences For up to $1.8 Billion
May 22 BIIB Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
May 22 RVPH RVPH: Enrollment Right Around the Corner
May 22 BIIB Biogen inks $1.8B deal to acquire immune drug developer HI-Bio
May 22 BIIB Biogen in up to $1.8 billion deal as rare diseases take center stage
May 22 BIIB Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22 BIIB Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B
May 21 PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a type of chronic lung disease characterized by a progressive and irreversible decline in lung function. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired and nail clubbing. Complications may include pulmonary hypertension, heart failure, pneumonia, or pulmonary embolism.The cause is unknown. Risk factors include cigarette smoking, certain viral infections, and a family history of the condition. The underlying mechanism involves scarring of the lungs. Diagnosis requires ruling out other potential causes and may be supported by a CT scan or lung biopsy. It is a type of interstitial lung disease (ILD).People often benefit from pulmonary rehabilitation and supplemental oxygen. Certain medications like pirfenidone or nintedanib may slow the progression of the disease. Lung transplantation may also be an option.About 5 million people are affected globally. The disease newly occurs in about 12 per 100,000 people per year. Those in their 60s and 70s are most commonly affected. Males are affected more often than females. Average life expectancy following diagnosis is about four years.

Browse All Tags